| P50 | author | Tristan Ferry | Q63379749 |
| | Yvan Jamilloux | Q63974456 |
| | Pascal Sève | Q90872467 |
| | Christiane Broussolle | Q116060355 |
| P2093 | author name string | Jérôme Honnorat | |
| | Sébastien Kerever | |
| P2860 | cites work | The human polyomavirus, JCV, uses serotonin receptors to infect cells | Q28294207 |
| | Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression | Q28376383 |
| | Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy | Q28478894 |
| | Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders | Q28740884 |
| | PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section | Q30613846 |
| | Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project | Q33383576 |
| | Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. | Q33502327 |
| | Tolerability and safety aspects of mirtazapine | Q34156657 |
| | Determinants of survival in progressive multifocal leukoencephalopathy | Q35012056 |
| | Metabolic profile of PML lesions in patients with and without IRIS: an observational study | Q36198630 |
| | Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy | Q36234255 |
| | Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name? | Q36544721 |
| | Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients | Q37206687 |
| | Mirtazapine overdose is unlikely to cause major toxicity | Q37489869 |
| | Evaluation of progressive multifocal leukoencephalopathy treatments in a Spanish cohort of HIV-infected patients: do protease inhibitors improve survival regardless of central nervous system penetration-effectiveness (CPE) score? | Q38065339 |
| | The CARE guidelines: consensus-based clinical case report guideline development | Q38137501 |
| | Progressive multifocal leukoencephalopathy and JC Virus-related disease in modern neurology practice | Q38422363 |
| | Reassessing the risk of natalizumab-associated PML. | Q40026025 |
| | Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV/AIDS patients in the current era. | Q42251011 |
| | Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study | Q45064421 |
| | The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy. | Q45740735 |
| | Progressive multifocal leukoencephalopathy in transplant recipients | Q56060082 |
| | Clinical Course and Prognostic Factors of Progressive Multifocal Leukoencephalopathy in Patients Treated with Highly Active Antiretroviral Therapy | Q58204816 |
| | Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapies | Q60962707 |
| | Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy | Q84114256 |
| P433 | issue | 10 | |
| P921 | main subject | progressive multifocal leukoencephalopathy | Q704930 |
| P304 | page(s) | 783-789 | |
| P577 | publication date | 2016-10-01 | |
| P1433 | published in | Clinical Drug Investigation | Q15753215 |
| P1476 | title | Treatment of Progressive Multifocal Leukoencephalopathy With Mirtazapine | |
| P478 | volume | 36 | |